Home LiteratureArticle Details
PMID: 29118008 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't Review

CTLA-4: a moving target in immunotherapy.

Blood ·Vol. 131 ·No. 1 ·2018-00-04 ·Pages 58-67

Rowshanravan B, Halliday N, Sansom DM

Abstract

CD28 and CTLA-4 are members of a family of immunoglobulin-related receptors that are responsible for various aspects of T-cell immune regulation. The family includes CD28, CTLA-4, and ICOS as well as other proteins, including PD-1, BTLA, and TIGIT. These receptors have both stimulatory (CD28, ICOS) and inhibitory roles (CTLA-4, PD-1, BTLA, and TIGIT) in T-cell function. Increasingly, these pathways are targeted as part of immune modulatory strategies to treat cancers, referred to generically as immune checkpoint blockade, and conversely to treat autoimmunity and CTLA-4 deficiency. Here, we focus on the biology of the CD28/CTLA-4 pathway as a framework for understanding the impacts of therapeutic manipulation of this pathway.

MeSH Terms
Animals Antibodies, Monoclonal/therapeutic use CTLA-4 Antigen/antagonists & inhibitors,immunology Humans Immunotherapy Neoplasms/drug therapy,immunology
Chemicals
Antibodies, Monoclonal CTLA-4 Antigen CTLA4 protein, human
Authors & Affiliations
3 authors, click to expand affiliations / ORCID
Rowshanravan Behzad ORCID
Institute of Immunity and Transplantation, Division of Infection & Immunity, University College London, Royal Free Hospital, London, United Kingdom.
Halliday Neil ORCID
Institute of Immunity and Transplantation, Division of Infection & Immunity, University College London, Royal Free Hospital, London, United Kingdom.
Sansom David M ORCID
Institute of Immunity and Transplantation, Division of Infection & Immunity, University College London, Royal Free Hospital, London, United Kingdom.
References (135)
135 references, click to expand
  1. Lymphoproliferative disorder in CTLA-4 knockout mice is characterized by CD28-regulated activation of Th2 responses.
    J Immunol. 1999 May 15;162(10):5784-91 PMID: 10229811
  2. Cutting edge: lymphoproliferative disease in the absence of CTLA-4 is not T cell autonomous.
    J Immunol. 1999 Aug 1;163(3):1128-31 PMID: 10415006
  3. Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation.
    J Exp Med. 1999 Aug 2;190(3):355-66 PMID: 10430624
  4. B7/CD28 costimulation is essential for the homeostasis of the CD4+CD25+ immunoregulatory T cells that control autoimmune diabetes.
    Immunity. 2000 Apr;12(4):431-40 PMID: 10795741
  5. Combination immunotherapy of primary prostate cancer in a transgenic mouse model using CTLA-4 blockade.
    Cancer Res. 2000 May 1;60(9):2444-8 PMID: 10811122
  6. A cellular calculus for signal integration by T cells.
    Nat Immunol. 2000 Sep;1(3):239-44 PMID: 10973282
  7. Structural basis for co-stimulation by the human CTLA-4/B7-2 complex.
    Nature. 2001 Mar 29;410(6828):604-8 PMID: 11279501
  8. Crystal structure of the B7-1/CTLA-4 complex that inhibits human immune responses.
    Nature. 2001 Mar 29;410(6828):608-11 PMID: 11279502
  9. Elucidating the autoimmune and antitumor effector mechanisms of a treatment based on cytotoxic T lymphocyte antigen-4 blockade in combination with a B16 melanoma vaccine: comparison of prophylaxis and therapy.
    J Exp Med. 2001 Aug 20;194(4):481-9 PMID: 11514604
  10. Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25(+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses.
    J Exp Med. 2001 Sep 17;194(6):823-32 PMID: 11560997
  11. RIPping notch apart: a new role for endocytosis in signal transduction?
    Sci STKE. 2000 Apr 25;2000(29):pe1 PMID: 11752592
  12. The CD28 signaling pathway regulates glucose metabolism.
    Immunity. 2002 Jun;16(6):769-77 PMID: 12121659
  13. The interaction properties of costimulatory molecules revisited.
    Immunity. 2002 Aug;17(2):201-10 PMID: 12196291
  14. T cell anergy.
    Annu Rev Immunol. 2003;21:305-34 PMID: 12471050
  15. Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients.
    Proc Natl Acad Sci U S A. 2003 Apr 15;100(8):4712-7 PMID: 12682289
  16. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma.
    Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8372-7 PMID: 12826605
  17. Rac-dependent trans-endocytosis of ephrinBs regulates Eph-ephrin contact repulsion.
    Nat Cell Biol. 2003 Oct;5(10):879-88 PMID: 12973357
  18. Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig.
    N Engl J Med. 2003 Nov 13;349(20):1907-15 PMID: 14614165
  19. B7-1 and B7-2 selectively recruit CTLA-4 and CD28 to the immunological synapse.
    Immunity. 2004 Sep;21(3):401-13 PMID: 15357951
  20. Autoimmunity in a phase I trial of a fully human anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibody with multiple melanoma peptides and Montanide ISA 51 for patients with resected stages III and IV melanoma.
    J Clin Oncol. 2005 Feb 1;23(4):741-50 PMID: 15613700
  21. CD28 costimulation of developing thymocytes induces Foxp3 expression and regulatory T cell differentiation independently of interleukin 2.
    Nat Immunol. 2005 Feb;6(2):152-62 PMID: 15640801
  22. Human CTLA4 knock-in mice unravel the quantitative link between tumor immunity and autoimmunity induced by anti-CTLA-4 antibodies.
    Blood. 2005 Nov 1;106(9):3127-33 PMID: 16037385
  23. Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4.
    J Clin Oncol. 2005 Sep 1;23(25):6043-53 PMID: 16087944
  24. Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a phase I/II study.
    Ann Surg Oncol. 2005 Dec;12(12):1005-16 PMID: 16283570
  25. Costimulatory receptors in a teleost fish: typical CD28, elusive CTLA4.
    J Immunol. 2006 Apr 1;176(7):4191-200 PMID: 16547256
  26. Impaired regulatory T cell function in germ-free mice.
    Eur J Immunol. 2006 Sep;36(9):2336-46 PMID: 16897813
  27. The reverse stop-signal model for CTLA4 function.
    Nat Rev Immunol. 2008 Feb;8(2):153-60 PMID: 18219311
  28. Trans-endocytosis of CD47 and SHPS-1 and its role in regulation of the CD47-SHPS-1 system.
    J Cell Sci. 2008 Apr 15;121(Pt 8):1213-23 PMID: 18349073
  29. Detailed analysis of immunologic effects of the cytotoxic T lymphocyte-associated antigen 4-blocking monoclonal antibody tremelimumab in peripheral blood of patients with melanoma.
    J Transl Med. 2008 May 01;6:22 PMID: 18452610
  30. CTLA4 blockade expands FoxP3+ regulatory and activated effector CD4+ T cells in a dose-dependent fashion.
    Blood. 2008 Aug 15;112(4):1175-83 PMID: 18523152
  31. Ctla-4 blockade confers lymphocyte resistance to regulatory T-cells in advanced melanoma: surrogate marker of efficacy of tremelimumab?
    Clin Cancer Res. 2008 Aug 15;14(16):5242-9 PMID: 18698043
  32. CTLA-4 blockade increases IFNgamma-producing CD4+ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients.
    Proc Natl Acad Sci U S A. 2008 Sep 30;105(39):14987-92 PMID: 18818309
  33. CTLA-4 control over Foxp3+ regulatory T cell function.
    Science. 2008 Oct 10;322(5899):271-5 PMID: 18845758
  34. Ctla-4 controls regulatory T cell peripheral homeostasis and is required for suppression of pancreatic islet autoimmunity.
    J Immunol. 2009 Jan 1;182(1):274-82 PMID: 19109158
  35. Intratumoral immune cell infiltrates, FoxP3, and indoleamine 2,3-dioxygenase in patients with melanoma undergoing CTLA4 blockade.
    Clin Cancer Res. 2009 Jan 1;15(1):390-9 PMID: 19118070
  36. Phase I/II trial of tremelimumab in patients with metastatic melanoma.
    J Clin Oncol. 2009 Mar 1;27(7):1075-81 PMID: 19139427
  37. Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies.
    J Exp Med. 2009 Aug 3;206(8):1717-25 PMID: 19581407
  38. Genetic polymorphisms in cytotoxic T-lymphocyte antigen 4 and cancer: the dialectical nature of subtle human immune dysregulation.
    Cancer Res. 2009 Aug 1;69(15):6011-4 PMID: 19638588
  39. Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study.
    Lancet Oncol. 2010 Feb;11(2):155-64 PMID: 20004617
  40. CTLA-4 suppresses the pathogenicity of self antigen-specific T cells by cell-intrinsic and cell-extrinsic mechanisms.
    Nat Immunol. 2010 Feb;11(2):129-35 PMID: 20037585
  41. Preoperative CTLA-4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical trial.
    Clin Cancer Res. 2010 May 15;16(10):2861-71 PMID: 20460488
  42. Tremelimumab in combination with exemestane in patients with advanced breast cancer and treatment-associated modulation of inducible costimulator expression on patient T cells.
    Clin Cancer Res. 2010 Jul 1;16(13):3485-94 PMID: 20479064
  43. Improved survival with ipilimumab in patients with metastatic melanoma.
    N Engl J Med. 2010 Aug 19;363(8):711-23 PMID: 20525992
  44. An enigmatic tail of CD28 signaling.
    Cold Spring Harb Perspect Biol. 2010 Aug;2(8):a002436 PMID: 20534709
  45. Spatiotemporal basis of CTLA-4 costimulatory molecule-mediated negative regulation of T cell activation.
    Immunity. 2010 Sep 24;33(3):326-39 PMID: 20870175
  46. Blockade of cytotoxic T-lymphocyte antigen-4 by ipilimumab results in dysregulation of gastrointestinal immunity in patients with advanced melanoma.
    Cancer Immun. 2010 Nov 24;10:11 PMID: 21090563
  47. Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4.
    Science. 2011 Apr 29;332(6029):600-3 PMID: 21474713
  48. Intrinsic and extrinsic control of peripheral T-cell tolerance by costimulatory molecules of the CD28/ B7 family.
    Immunol Rev. 2011 May;241(1):180-205 PMID: 21488898
  49. A motif in the V3 domain of the kinase PKC-θ determines its localization in the immunological synapse and functions in T cells via association with CD28.
    Nat Immunol. 2011 Oct 02;12(11):1105-12 PMID: 21964608
  50. The emerging role of CTLA4 as a cell-extrinsic regulator of T cell responses.
    Nat Rev Immunol. 2011 Nov 25;11(12):852-63 PMID: 22116087
  51. Constitutive clathrin-mediated endocytosis of CTLA-4 persists during T cell activation.
    J Biol Chem. 2012 Mar 16;287(12):9429-40 PMID: 22262842
  52. Abatacept for Crohn's disease and ulcerative colitis.
    Gastroenterology. 2012 Jul;143(1):62-69.e4 PMID: 22504093
  53. Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study.
    J Clin Oncol. 2012 Jun 10;30(17):2046-54 PMID: 22547592
  54. Deleterious mutations in LRBA are associated with a syndrome of immune deficiency and autoimmunity.
    Am J Hum Genet. 2012 Jun 8;90(6):986-1001 PMID: 22608502
  55. Notch ligand endocytosis generates mechanical pulling force dependent on dynamin, epsins, and actin.
    Dev Cell. 2012 Jun 12;22(6):1299-312 PMID: 22658936
  56. Cutting edge: cell-extrinsic immune regulation by CTLA-4 expressed on conventional T cells.
    J Immunol. 2012 Aug 1;189(3):1118-22 PMID: 22753931
  57. Cutting edge: CTLA-4 on effector T cells inhibits in trans.
    J Immunol. 2012 Aug 1;189(3):1123-7 PMID: 22753941
  58. Why must T cells be cross-reactive?
    Nat Rev Immunol. 2012 Sep;12(9):669-77 PMID: 22918468
  59. Cell-intrinsic and -extrinsic control of Treg-cell homeostasis and function revealed by induced CD28 deletion.
    Eur J Immunol. 2013 Jan;43(1):188-93 PMID: 23065717
  60. An obligate cell-intrinsic function for CD28 in Tregs.
    J Clin Invest. 2013 Feb;123(2):580-93 PMID: 23281398
  61. Virus-specific CD4(+) memory-phenotype T cells are abundant in unexposed adults.
    Immunity. 2013 Feb 21;38(2):373-83 PMID: 23395677
  62. Patterns of onset and resolution of immune-related adverse events of special interest with ipilimumab: detailed safety analysis from a phase 3 trial in patients with advanced melanoma.
    Cancer. 2013 May 1;119(9):1675-82 PMID: 23400564
  63. The BEACH is hot: a LYST of emerging roles for BEACH-domain containing proteins in human disease.
    Traffic. 2013 Jul;14(7):749-66 PMID: 23521701
  64. Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study.
    Ann Oncol. 2013 Jul;24(7):1813-21 PMID: 23535954
  65. Comparison of the intracellular trafficking itinerary of ctla-4 orthologues.
    PLoS One. 2013;8(4):e60903 PMID: 23565286
  66. The lymphoid lineage-specific actin-uncapping protein Rltpr is essential for costimulation via CD28 and the development of regulatory T cells.
    Nat Immunol. 2013 Aug;14(8):858-66 PMID: 23793062
  67. CD28-inducible transcription factor DEC1 is required for efficient autoreactive CD4+ T cell response.
    J Exp Med. 2013 Jul 29;210(8):1603-19 PMID: 23878307
  68. Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma.
    J Exp Med. 2013 Aug 26;210(9):1695-710 PMID: 23897981
  69. Rapid effector function of memory CD8+ T cells requires an immediate-early glycolytic switch.
    Nat Immunol. 2013 Oct;14(10):1064-72 PMID: 23955661
  70. Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial.
    Lancet Oncol. 2013 Oct;14(11):1104-1111 PMID: 24035405
  71. CD28 and ITK signals regulate autoreactive T cell trafficking.
    Nat Med. 2013 Dec;19(12):1632-7 PMID: 24270545
  72. Inhibition of the kinase Csk in thymocytes reveals a requirement for actin remodeling in the initiation of full TCR signaling.
    Nat Immunol. 2014 Feb;15(2):186-94 PMID: 24317039
  73. Human regulatory T cells are selectively activated by low-dose application of the CD28 superagonist TGN1412/TAB08.
    Eur J Immunol. 2014 Apr;44(4):1225-36 PMID: 24374661
  74. Degradation of connexins and gap junctions.
    FEBS Lett. 2014 Apr 17;588(8):1221-9 PMID: 24486527
  75. Rab8 binding to immune cell-specific adaptor LAX facilitates formation of trans-Golgi network-proximal CTLA-4 vesicles for surface expression.
    Mol Cell Biol. 2014 Apr;34(8):1486-99 PMID: 24515439
  76. Inducible deletion of CD28 prior to secondary nippostrongylus brasiliensis infection impairs worm expulsion and recall of protective memory CD4⁺ T cell responses.
    PLoS Pathog. 2014 Feb 06;10(2):e1003906 PMID: 24516382
  77. Inter-cellular exchange of cellular components via VE-cadherin-dependent trans-endocytosis.
    PLoS One. 2014 Mar 06;9(6):e90736 PMID: 24603875
  78. Protein kinase C-η controls CTLA-4-mediated regulatory T cell function.
    Nat Immunol. 2014 May;15(5):465-72 PMID: 24705298
  79. Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial.
    Lancet Oncol. 2014 Jun;15(7):700-12 PMID: 24831977
  80. Improved survival with T cell clonotype stability after anti-CTLA-4 treatment in cancer patients.
    Sci Transl Med. 2014 May 28;6(238):238ra70 PMID: 24871131
  81. The self-obsession of T cells: how TCR signaling thresholds affect fate 'decisions' and effector function.
    Nat Immunol. 2014 Sep;15(9):815-23 PMID: 25137456
  82. A transendocytosis perspective on the CD28/CTLA-4 pathway.
    Adv Immunol. 2014;124:95-136 PMID: 25175774
  83. Immune dysregulation in human subjects with heterozygous germline mutations in CTLA4.
    Science. 2014 Sep 26;345(6204):1623-1627 PMID: 25213377
  84. Autosomal dominant immune dysregulation syndrome in humans with CTLA4 mutations.
    Nat Med. 2014 Dec;20(12):1410-1416 PMID: 25329329
  85. T cell signaling. Antigen affinity, costimulation, and cytokine inputs sum linearly to amplify T cell expansion.
    Science. 2014 Nov 28;346(6213):1123-7 PMID: 25430770
  86. Detection of self-reactive CD8⁺ T cells with an anergic phenotype in healthy individuals.
    Science. 2014 Dec 19;346(6216):1536-40 PMID: 25525252
  87. CTLA-4 controls follicular helper T-cell differentiation by regulating the strength of CD28 engagement.
    Proc Natl Acad Sci U S A. 2015 Jan 13;112(2):524-9 PMID: 25548162
  88. Confusing signals: recent progress in CTLA-4 biology.
    Trends Immunol. 2015 Feb;36(2):63-70 PMID: 25582039
  89. A transendocytosis model of CTLA-4 function predicts its suppressive behavior on regulatory T cells.
    J Immunol. 2015 Mar 1;194(5):2148-59 PMID: 25632005
  90. The chromatin-modifying enzyme Ezh2 is critical for the maintenance of regulatory T cell identity after activation.
    Immunity. 2015 Feb 17;42(2):227-238 PMID: 25680271
  91. The transcription factor NFAT promotes exhaustion of activated CD8⁺ T cells.
    Immunity. 2015 Feb 17;42(2):265-278 PMID: 25680272
  92. Efficacy and safety of an intensified schedule of tremelimumab for chemotherapy-resistant malignant mesothelioma: an open-label, single-arm, phase 2 study.
    Lancet Respir Med. 2015 Apr;3(4):301-9 PMID: 25819643
  93. Combinatorial proteomic analysis of intercellular signaling applied to the CD28 T-cell costimulatory receptor.
    Proc Natl Acad Sci U S A. 2015 Mar 31;112(13):E1594-603 PMID: 25829543
  94. The future of immune checkpoint therapy.
    Science. 2015 Apr 3;348(6230):56-61 PMID: 25838373
  95. Pembrolizumab versus Ipilimumab in Advanced Melanoma.
    N Engl J Med. 2015 Jun 25;372(26):2521-32 PMID: 25891173
  96. Clonal Deletion Prunes but Does Not Eliminate Self-Specific αβ CD8(+) T Lymphocytes.
    Immunity. 2015 May 19;42(5):929-41 PMID: 25992863
  97. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.
    N Engl J Med. 2015 Jul 2;373(1):23-34 PMID: 26027431
  98. AUTOIMMUNE DISEASE. Patients with LRBA deficiency show CTLA4 loss and immune dysregulation responsive to abatacept therapy.
    Science. 2015 Jul 24;349(6246):436-40 PMID: 26206937
  99. 1,25(OH)2D3 Promotes the Efficacy of CD28 Costimulation Blockade by Abatacept.
    J Immunol. 2015 Sep 15;195(6):2657-65 PMID: 26276872
  100. Deletion of CTLA-4 on regulatory T cells during adulthood leads to resistance to autoimmunity.
    J Exp Med. 2015 Sep 21;212(10):1603-21 PMID: 26371185
  101. Integrated molecular analysis of adult T cell leukemia/lymphoma.
    Nat Genet. 2015 Nov;47(11):1304-15 PMID: 26437031
  102. Abatacept alleviates severe autoimmune symptoms in a patient carrying a de novo variant in CTLA-4.
    J Allergy Clin Immunol. 2016 Jan;137(1):327-330 PMID: 26478010
  103. Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota.
    Science. 2015 Nov 27;350(6264):1079-84 PMID: 26541610
  104. CD4+ T Cell Tolerance to Tissue-Restricted Self Antigens Is Mediated by Antigen-Specific Regulatory T Cells Rather Than Deletion.
    Immunity. 2015 Nov 17;43(5):896-908 PMID: 26572061
  105. Recurrent activating mutations of CD28 in peripheral T-cell lymphomas.
    Leukemia. 2016 May;30(5):1062-70 PMID: 26719098
  106. Tolerance is established in polyclonal CD4(+) T cells by distinct mechanisms, according to self-peptide expression patterns.
    Nat Immunol. 2016 Feb;17(2):187-95 PMID: 26726812
  107. The extended phenotype of LPS-responsive beige-like anchor protein (LRBA) deficiency.
    J Allergy Clin Immunol. 2016 Jan;137(1):223-230 PMID: 26768763
  108. Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis.
    Nat Commun. 2016 Feb 02;7:10391 PMID: 26837003
  109. Induction of autoimmune disease by deletion of CTLA-4 in mice in adulthood.
    Proc Natl Acad Sci U S A. 2016 Apr 26;113(17):E2383-92 PMID: 27071130
  110. Interrupting CD28 costimulation before antigen rechallenge affects CD8(+) T-cell expansion and effector functions during secondary response in mice.
    Eur J Immunol. 2016 Jul;46(7):1644-55 PMID: 27122236
  111. Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination.
    Nat Rev Clin Oncol. 2016 Aug;13(8):473-86 PMID: 27141885
  112. The rise and fall of the CD28 superagonist TGN1412 and its return as TAB08: a personal account.
    FEBS J. 2016 Sep;283(18):3325-34 PMID: 27191544
  113. CD28 Costimulation: From Mechanism to Therapy.
    Immunity. 2016 May 17;44(5):973-88 PMID: 27192564
  114. Clonal expansion of CD8 T cells in the systemic circulation precedes development of ipilimumab-induced toxicities.
    Proc Natl Acad Sci U S A. 2016 Oct 18;113(42):11919-11924 PMID: 27698113
  115. Fulminant Myocarditis with Combination Immune Checkpoint Blockade.
    N Engl J Med. 2016 Nov 03;375(18):1749-1755 PMID: 27806233
  116. Efficient Culture of Human Naive and Memory B Cells for Use as APCs.
    J Immunol. 2016 Nov 15;197(10):4163-4176 PMID: 27815447
  117. Immune Toxicities Elicted by CTLA-4 Blockade in Cancer Patients Are Associated with Early Diversification of the T-cell Repertoire.
    Cancer Res. 2017 Mar 15;77(6):1322-1330 PMID: 28031229
  118. Identifying functional defects in patients with immune dysregulation due to LRBA and CTLA-4 mutations.
    Blood. 2017 Mar 16;129(11):1458-1468 PMID: 28159733
  119. Structural basis for cancer immunotherapy by the first-in-class checkpoint inhibitor ipilimumab.
    Proc Natl Acad Sci U S A. 2017 May 23;114(21):E4223-E4232 PMID: 28484017
  120. Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4.
    Science. 1995 Nov 10;270(5238):985-8 PMID: 7481803
  121. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4.
    Immunity. 1995 Nov;3(5):541-7 PMID: 7584144
  122. CD28 costimulation can promote T cell survival by enhancing the expression of Bcl-XL.
    Immunity. 1995 Jul;3(1):87-98 PMID: 7621080
  123. B7/BB1, the ligand for CD28, is expressed on repeatedly activated human T cells in vitro.
    Eur J Immunol. 1993 Jan;23(1):295-8 PMID: 7678229
  124. B70 antigen is a second ligand for CTLA-4 and CD28.
    Nature. 1993 Nov 4;366(6450):76-9 PMID: 7694153
  125. Enhancement of antitumor immunity by CTLA-4 blockade.
    Science. 1996 Mar 22;271(5256):1734-6 PMID: 8596936
  126. T cell activation determined by T cell receptor number and tunable thresholds.
    Science. 1996 Jul 5;273(5271):104-6 PMID: 8658175
  127. Intracellular trafficking of CTLA-4 and focal localization towards sites of TCR engagement.
    Immunity. 1996 Jun;4(6):535-43 PMID: 8673700
  128. Duration of TCR stimulation determines costimulatory requirement of T cells.
    Immunity. 1996 Jul;5(1):41-52 PMID: 8758893
  129. B7-1 and B7-2 have overlapping, critical roles in immunoglobulin class switching and germinal center formation.
    Immunity. 1997 Mar;6(3):303-13 PMID: 9075931
  130. Tyrosine phosphorylation controls internalization of CTLA-4 by regulating its interaction with clathrin-associated adaptor complex AP-2.
    Immunity. 1997 May;6(5):583-9 PMID: 9175836
  131. Interaction of CTLA-4 with the clathrin-associated protein AP50 results in ligand-independent endocytosis that limits cell surface expression.
    J Immunol. 1997 Jul 1;159(1):144-51 PMID: 9200449
  132. Interaction of CTLA-4 with AP50, a clathrin-coated pit adaptor protein.
    Proc Natl Acad Sci U S A. 1997 Aug 19;94(17):9273-8 PMID: 9256472
  133. The emerging role of CTLA-4 as an immune attenuator.
    Immunity. 1997 Oct;7(4):445-50 PMID: 9354465
  134. Studies using antigen-presenting cells lacking expression of both B7-1 (CD80) and B7-2 (CD86) show distinct requirements for B7 molecules during priming versus restimulation of Th2 but not Th1 cytokine production.
    J Immunol. 1998 Sep 15;161(6):2762-71 PMID: 9743334
  135. Molecular basis of T cell inactivation by CTLA-4.
    Science. 1998 Dec 18;282(5397):2263-6 PMID: 9856951
Article Info
Journal
Blood
Abbr.
Blood
ISSN
1528-0020
DOI
10.1182/blood-2017-06-741033
Published
2018-00-04
Epub
2017-00-08
Pages
58-67
Language
English
Region
United States
NLM ID
7603509
PMCID
PMC6317697
Subset
IM
Grants
Wellcome Trust · United Kingdom
Biotechnology and Biological Sciences Research Council · BB/M009203/1 · United Kingdom
External Links
PubMed source DOI: 10.1182/blood-2017-06-741033 PMC Full Text View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2